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Abstract
Background: Extensive allelic matching in the human leukocyte antigen (HLA) genes is regarded
as a prerequisite for good clinical success of allogeneic haematopoietic stem cell transplantation
(HSCT). Also other genetic factors can be assumed to play a role in preventing and controlling the
complications associated with allogeneic HSCT, in particular graft-versus-host disease (GvHD).
Interleukin-10 (IL-10) and its receptor (IL-10R), key regulators of the immune response, are among
these candidates. We studied the association of IL-10 and IL-10Rβ gene polymorphisms with the
occurrence of GvHD in 309 HLA-identical sibling donor and recipient pairs.
Results: The difference in genotypic IL-10 production between patient and donor in combination
with patient IL-10Rβ A/A genotype predisposed strongly to acute GvHD (OR = 7.15, p =
0.000023). On the other hand, a combination of same genotypic IL-10 production with patient IL-
10Rβ A/A genotype protected from chronic GvHD (OR = 0.407, p = 0.0097).
Conclusion: Our results suggest that IL-10 and IL-10Rβ genes have a synergistic effect on the risk
of GvHD.
Background
Extensive allelic matching in the human leukocyte antigen
(HLA) genes between recipient and donor is regarded as a
prerequisite for good clinical success of allogeneic hae-
matopoietic stem cell transplantation (HSCT) [1]. Graft-
versus-host disease (GvHD) can not be totally avoided
even with fully HLA-matched sibling donors or by using
current GvHD prophylaxis, indicating complex and mul-
tifactorial nature of GvHD. This has lead into search of
novel genetic factors, in addition to the HLA genes, to pre-
vent and predict the occurrence of GvHD. Genes for killer
cell immunoglobulin like receptors (KIR), KIR ligands
and minor histocompatibility antigens as well as several
cytokines and cytokine receptors have obtained a consid-
erable interest [2-4].
Cytokine interleukin 10 (IL-10) is a good functional can-
didate for GvHD-related gene [5,6]. Previous studies have
shown that patient or donor IL-10 genotypes separately
associate with both acute and chronic GvHD [6-9]. IL-10
is produced by a variety of different cells, of both haemat-
opoietic and non-haematopoietic lineages [10]. IL-10 is
Published: 4 May 2009
BMC Immunology 2009, 10:24 doi:10.1186/1471-2172-10-24
Received: 23 June 2008
Accepted: 4 May 2009
This article is available from: http://www.biomedcentral.com/1471-2172/10/24
© 2009 Sivula et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Immunology 2009, 10:24 http://www.biomedcentral.com/1471-2172/10/24
Page 2 of 7
(page number not for citation purposes)
usually regarded as a potent suppressor of the immune
responses and hence it is thought to be useful in prevent-
ing GvHD. However, it has also been shown to have some
immunostimulatory effects [11-13]. Interleukin 10 recep-
tor beta (IL-10Rβ) is also expressed on several cell types,
and its role varies depending on the cell type it is
expressed on [14]. In haematopoietic cell lineages IL-
10Rβ functions as a part of IL-10 receptor together with IL-
10 receptor alpha (IL-10Rα). IL-10Rα, the IL-10 specific
part of the receptor complex, is only expressed on haemat-
opoietic cells [5]. Thus in haematopoietic cells IL-10Rβ is
mediating the IL-10 signal. In many non-haematopoietic
cell lineages IL-10Rβ functions as a part of a receptor for
other cytokines [14].
To address the role of IL-10 and IL-10Rβ in HSCT we here
report the effects of polymorphisms in these genes on the
incidence of acute and chronic GvHD in 309 Finnish
HSCT recipients who had an HLA identical sibling donor.
In particular, we addressed the questions of interplay of
patient- and donor-specific factors of IL-10 and IL-10Rβ
genes.
Results
Altogether 309 allogeneic HSCT recipients and their HLA-
identical sibling donors were included in the study. The
demographic and other background information is given
in Table 1. Genetic variation in IL-10 and IL-10Rβ genes
was studied and genetic association with the occurrence of
GvHD in the patients was tested.
1. Genotype and haplotype association of IL-10 and IL-
10Rβ gene polymorphisms with GvHD
The distributions of genotypes and haplotypes in patients
and donors were studied for their association with the
occurrence of acute (none versus grade III–IV) and
chronic (none versus extensive) GvHD (Additional files 1
and 2).
In the patients, the genotype rs1800872 A/A in IL-10 gene
predisposed to grade III–IV acute GvHD (p = 0.031, OR =
3.83) when compared to other genotypes (A/C and C/C).
As a result of strong linkage disequilibrium between the
IL-10 gene markers, the same association was also
detected for the rs1800872 – rs1800896 haplotypes
(Additional files 1 and 2). In the IL-10Rβ gene, patient's
A/A genotype predisposed to acute GvHD (p = 0.0035, OR
= 3.88) and A/G genotype showed protection from it (p =
0.017, OR = 0.30).
When the patients and donors were stratified based on
their IL-10 and IL-10Rβ genotypes together, this approach
did not suggest any novel genetic association.
In the patients, none of the genotypes of IL-10 or IL-10Rβ
showed statistically significant association with chronic
GvHD. In the donors, no genotypes or haplotypes showed
statistically significant association with either chronic or
acute GvHD (Additional files 1 and 2).
Previously, Lin et al. [7] described that a certain combina-
tion of patient IL-10 and donor IL-10Rβ polymorphisms
protected very strongly from acute GvHD. Hence, we car-
ried out similar analysis (Table 2). We also found that
none of the three sibling pairs in our data set with IL-10
rs1800872 A/A (patient) – IL-10Rβ rs28341676 G/G
(donor) genotypes actually resulted in acute GvHD, but
no statistical significancy or similar trend of decreasing
acute GvHD frequency as Lin et al. observed toward this
genotype combination could be seen.
Table 1: Sample demographics
Patient age, years mean (range) 47 (17–66)
Donor age, years mean (range) 45 (11–68)
Diagnosis, frequency
Acute myeloid leukaemia 77
Multiple myeloma 54
Acute lymphoid leukaemia 48
Chronic lymphoid leukaemia 45
Myelodysplastic syndrome 23
Chronic myeloid leukaemia 13
Non-Hodgkin lymphoma 13
Other 36
Disease status
Good prognosis 148
Bad prognosis 142
Gender, patient-donor
male-male 82
male-female 67
female-male 76
female-female 63
Graft origin
Peripheral blood 128
Bone marrow 162
Conditioning
Myeloablative 233
Other 57
GvHD prevention
Cyclosporine, Methotrexate and Methylprednisolone 207
Cyclosporine and Mycophenolate Mofetil 46
Cyclosporine and Methotrexate 37
Acute GvHD
No 197
grade III–IV 29
Chronic GvHD
No 117
Extensive 72BMC Immunology 2009, 10:24 http://www.biomedcentral.com/1471-2172/10/24
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2. Associations with predicted IL-10 production levels
Genotype classes with different predicted production lev-
els were tested for their association with the occurrence of
GvHD but no statistically significant results could be
found. However, patient intermediate genotypic produc-
tion level was borderline protective from acute GvHD (p
= 0.073, OR = 0.431).
We furthermore subdivided the study group based on
their IL-10Rβ genotype and whether the donor – recipient
pair had the same or different production level of IL-10
(Additional file 3). Those patients with the IL-10Rβ A/A
genotype who received the graft from a donor with a dif-
ferent predicted IL-10 level to that of the recipient, had a
very high risk for acute GvHD (p = 0.000023, OR = 7.15).
Similarly, when the IL-10Rβ A/A homozygous patients
received a graft with a same IL-10 production level, they
were protected from chronic GvHD (p = 0.0097, OR =
0.407; Additional file 3).
3. Multivariate analysis
Logistic regression multivariate analysis was then per-
formed to test if the statistically significant results
observed in univariate analyses would hold, when tested
in the context of other known factors influencing GvHD;
disease status (good prognosis versus bad prognosis), gen-
der match (male versus female donor), graft origin (bone
marrow versus peripheral blood), pre-transplantation
conditioning (myeloablative versus other) and aGvHD as
a risk factor for cGvHD. All statistically significant results
of univariate IL-10 and IL-10Rβ remained significant in
multivariable analyses. Results of these analyses are
shown in Table 3. We also performed multivariable anal-
yses to see if the studied IL-10 and IL-10Rβ polymor-
phisms correlated with the other factors used in these
analysis. These results showed no correlation between dis-
ease status, gender match, graft origin and pre-transplan-
tation conditioning, and the IL-10 and IL-10Rβ
polymorphisms.
Discussion
In the present study we analysed the role of IL-10 and IL-
10Rβ SNPs on the incidence of acute and chronic GvHD
after HSCT between HLA-identical siblings. Previously
published studies on interaction of IL-10 and HSCT have
found association between IL-10 polymorphism and
GvHD outcome [6,8,9,15-18]. In these studies the results
predominantly rely on polymorphisms of either recipient
or donor. Here we addressed the question also by study-
ing the association of the SNPs with GvHD in biologically
more meaningful context; that is analysing simultane-
ously both donor and patient genotypes.
In our analysis patient IL-10 rs1800872 genotype A/A was
associated with worse acute GvHD outcome (Additional
file 1 and Table 3). Similar result was also observed with
rs1800896 and rs1800872 genotype combination AA/AA.
Also patient IL-10Rβ rs28341676 genotype affected the
risk of developing GvHD. Patient IL-10Rβ rs28341676 A/
A predisposed to and A/G protected from grades III–IV
acute GvHD. Donor IL-10 rs1800896 and rs1800872 or
IL-10Rβ rs28341676 polymorphisms did not have any
clear effect on the GvHD outcome (Additional file 2).
Because the cells of the graft are mainly haematopoietic
cells, the effect of IL-10Rβ polymorphism on the donor
side is restricted to recognition of IL-10. Since most of the
patient's original haematopoietic cells are eliminated, the
effect of IL-10Rβ on patient side is largely restricted to the
signalling of other cytokines where the IL-10Rβ also func-
tions as a part of the receptor complex. Cytokines known
to date to utilise IL-10Rβ are IL-10, IL-22, IL-26, IL-28A,
IL-28B and IL-29 [14]. Since donor IL-10Rβ had no signif-
icance on GvHD predisposition, the effects of IL-10Rβ
polymorphism would seem to rely largely on functions of
these other cytokines utilizing IL-10Rβ in their signalling.
When analysing both the patient and donor IL-10 geno-
types the results showed a trend for lower risk of develop-
ing GvHD when both had similar IL-10 production levels
estimated from genotypes (Additional file 3). Similar
results were also seen by Bertinetto et al [18]. In their
study the presence of IL-10 rs180087 G allele in both
patient and donor was associated with a trend for lower
risk of developing GvHD. The rationale for this is the fact
that IL-10 is a strong regulator of immune system and it
might be that either higher or lower production level of
the protein as compared to original one would not be
Table 2: Incidence of grade III–IV acute GvHD according to patient IL-10 (-592) rs1800872 and donor IL-10Rβ(+238) rs28341676 
genotypes/all cases (percent)
Patient IL-10 rs1800872
A/A A/C C/C
Donor IL-10Rβ rs28341676 A/A 3/8 (38%) 5/53 (9%) 9/90 (10%)
A/G 2/5 (40%) 4/32 (13%) 4/70 (6%)
G/G 0/3 (0%) 0/12 (0%) 1/24 (4%)BMC Immunology 2009, 10:24 http://www.biomedcentral.com/1471-2172/10/24
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optimal for the patient's immune system. The effect of
patient IL-10Rβ was also amplified when analyzed
together with IL-10 production level. IL-10Rβ A/A
strongly predisposed to acute GvHD when patient and
donor IL-10 production level differed, but protected from
chronic GvHD when patient and donor had similar IL-10
production level (Additional file 3 and Table 3).
We were not able to reproduce most of the significant
results of Lin et al [7] with our study material. In our
results the donor IL-10Rβ had no significant effect on the
GvHD even in combination with IL-10 polymorphisms.
Also, patient IL-10 rs1800872 A/A predisposed to acute
GvHD (Additional file 1 p = 0.031, OR = 3.83). However,
as Lin et al also observed, no acute GvHD cases were
present among those three pairs with the combination of
patient IL-10 rs1800872 A/A and donor IL-10Rβ
rs28341676 G/G (Table 2). Compared to our results, in
Lin et al study the frequency of IL-10 rs1800872 A allele
was higher. This might in part explain the striking differ-
ence between our results. The rs1800872 A allele is often
associated with lower risk of developing GvHD, but there
are also studies which show similar association as we
found [6,18]. It is possible that the rs1800872 is not it self
affecting to the risk of GvHD, but is in linkage disequilib-
rium with the actual effector. In different populations this
linkage might vary and cause the discrepancy in the
results.
In analyses of IL-10Rβ rs28341676 the results differed
between acute and chronic GvHD. Patient IL-10Rβ A/A
predisposed to acute GvHD and seemed to protect from
chronic GvHD. The different effect of IL-10Rβ polymor-
phism between acute GvHD and chronic GvHD and over-
all weaker results in chronic GvHD can be understood by
the immunologic differences between acute and chronic
GvHD. During the period of which acute GvHD is
observed, the immune system is just starting to reconsti-
tute anew after the HSCT. Also, many of the effector cells
had been developed within the donor. In many cell line-
Table 3: Multivariable logistic regression analysis of acute and chronic GvHD
Acute GvHD BS . E . p
Disease status 0.92 0.47 0.053
Gender match -0.29 0.50 0.56
Graft origin 0.34 0.50 0.49
Conditioning 0.055 0.60 0.93
Patient IL10 rs1800872 A/A 1.30 0.60 0.031
Constant -2.65 0.53
Acute GvHD BS . E . p
Disease status 1.26 0.53 0.017
Gender match -0.32 0.50 0.53
Graft origin 0.13 0.49 0.80
Conditioning -0.11 0.61 0.85
Patient IL10Rβ rs28341676 A/A 1.33 0.46 0.0041
Constant -3.13 0.58
Acute GvHD BS . E . p
Disease status 1.26 0.53 0.017
Gender match -0.39 0.56 0.49
Graft origin 0.09 0.52 0.86
Conditioning -0.52 0.67 0.44
IL-10 production level different and patient IL-10Rβ A/A 2.16 0.49 0.0000088
Constant -3.02 0.56
Chronic GvHD BS . E . p
Disease status 0.38 0.50 0.50
Gender match -1.20 0.55 0.028
Graft origin -1.58 0.48 0.0010
Conditioning 1.10 0.65 0.087
aGvHD 2.64 0.95 0.0052
IL-10 production level same and patient IL-10Rβ A/A -1.18 0.50 0.017
Constant 0.58 0.43BMC Immunology 2009, 10:24 http://www.biomedcentral.com/1471-2172/10/24
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ages their numbers start rising only well after the usual
100 days time limit of acute GvHD diagnosis. More cells
of donor origin are developing within the recipient during
chronic GvHD. The immune system is more mature and
complex than in the newly transplanted patient [19].
Notably, amounts of regulatory cells rise only relatively
late in immune reconstitution [20]. The full reconstitu-
tion of immune system after transplantation may take
years. Hence it is not surprising that IL-10 and IL-10Rβ
polymorphisms have less effect in chronic GvHD than in
acute GvHD. This could also explain the opposing effect
of IL-10Rβ polymorphism in acute GvHD and chronic
GvHD.
We are fully aware of the possible problems in analyzing
all the transplantations as a single group. Grafting periph-
eral blood stem cells instead of bone marrow cells predis-
poses to higher incidence of chronic GvHD. Also pre-
treatment conditioning, fully myeloablative versus
reduced intensity conditioning, highly affects the compli-
cations after HSCT. To address this issue we performed
logistic regression multivariate analysis to test the results
of univariate analyses in the context of known GvHD
affecting factors; disease status, gender match, graft origin,
pre-transplantation conditioning and aGvHD as a risk fac-
tor for cGvHD. All the statistically significant results from
univariate analyses remained significant in the multivari-
ate analyses (Table 3). The p-values in this study were not
corrected for multiple comparisons. These results need to
be validated in other cohorts and further studies are also
needed to clarify the relationships between IL-10 and IL-
10Rβ.
Conclusion
We didobserve synergistic effect between IL-10 and IL-
10Rβ in predisposition to GvHD. The effect of IL-10Rβ
polymorphism was strengthened when it was analysed
together with IL-10 polymorphisms. In our samples simi-
larity of IL-10 production level was associated with lower
incidence of both acute and chronic GvHD. Different
effect of IL-10Rβ genotype in acute GvHD and chronic
GvHD could be explained by the developing immune sys-
tem, arise of new regulatory cells and passing cytokine
storm associated with the transplantation.
Methods
Patients
Altogether 309 adult allogeneic HSCT recipients and their
HLA-identical sibling donors were included in this retro-
spective study. All transplantations were performed in a
single centre (Department of Medicine, Helsinki Univer-
sity Central Hospital, Helsinki, Finland) between years
1993 and 2005. Clinical data were collected on diagnosis,
age, gender match, transplantation protocol, date of trans-
plantation and acute GvHD and chronic GvHD manifes-
tation. GvHD was diagnosed and graded according to
standard criteria [21]. Patient and donor descriptive
demographics are shown in Table 1.
This study was approved by the Ethical Review Board of
the Helsinki University Hospital, Helsinki, Finland.
IL-10 and IL-10Rβ genotyping
Two single nucleotide polymorphisms (SNPs) in IL-10
and one in IL-10Rβ were genotyped. The IL-10 SNPs at
locations -1082 (rs1800896) and -592 (rs1800872) and
the IL-10Rβ SNP at location +238 (rs28341676) were
typed using restriction fragment length polymorphism
method as described earlier [7,22]. EcoNI recognition site
primers and restriction enzyme was used for IL-10.
In the Finnish population, the selected two markers for IL-
10 tag completely the often used three-marker haplotype
(-1082 A/G (rs1800896), -819 T/C (rs1800871), and -592
A/C (rs1800872)) for the gene [23].
Statistical analysis
To analyse the effect of IL-10 and IL-10Rβ polymorphisms
on the GvHD outcome we used different combinations of
patient and donor genotyping data. We (i) analysed IL-10
and IL-10Rβ genotypes and haplotypes separately in
patients and donors, and (ii) combined the genotyping
data from each patient-donor pair. We also (iii) grouped
the IL-10 genotypes into three production level groups:
high, intermediate and low producing. These groups are
based on the effect of IL-10 polymorphisms on the level
of protein production as published earlier [24,25]: IL-10
rs1800896 (SNP1) and rs1800872 (SNP2) genotype com-
bination (SNP1SNP2/SNP1SNP2) GC/GC belongs to
high producing, GC/AC and GC/AA to intermediate pro-
ducing, and AC/AC, AC/AA and AA/AA to low producing
group.
Analyses of different IL-10 and IL-10Rβ combinations
were done in relation to the acute GvHD and chronic
GvHD incidence using χ2 or Fisher's exact tests. Recipients
with acute GvHD of grade III–IV and their donors formed
the positive group which was compared to patients with
no acute GvHD and their donors. Chronic GvHD positive
group patients had extensive chronic GvHD and their con-
trols had no chronic GvHD. To test the statistically signif-
icant results of univariate analyses in the context of other
risk factors we constructed a multivariable logistic regres-
sion model adjusted for disease status, gender match, graft
origin and pre-transplantation conditioning. We also
included aGvHD as a risk factor for cGvHD. The SPSS for
Windows v15.0 software (SPSS Inc., Chicago, IL, USA)
was used for the analyses. All p-values are considered as
two-sided and uncorrected for multiple testing. P-values
under 0.05 were regarded to indicate statistical signifi-
cance.BMC Immunology 2009, 10:24 http://www.biomedcentral.com/1471-2172/10/24
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